Hoth Therapeutics secures a U.S. patent for exon-skipping allergy therapy. Read what this means for immunology strategy, clinical risk, and future drug development.
BioLife Solutions expands into cytokines through a Qkine agreement. Find out what this means for CGT manufacturing workflows and supplier strategy.
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in CIAS. Discover what the upcoming data could mean for precision psychiatry.
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.
SkyMD launches statewide online therapy in New Mexico. Find out what this expansion means for access, regulation, and teletherapy adoption.
PTC Therapeutics has withdrawn its U.S. filing for Translarna. Find out what this means for Duchenne drug development and FDA expectations.
UTulsa-backed BioReact targets bioprocess inefficiencies with AI analytics. Discover what this investment could change for biopharma development and manufacturing.
Innovent Biologics advances IBI354 into phase 3 first-line HER2-positive breast cancer. Find out what this means for ADC competition and clinical practice.
CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.